A TWINSS Extension Trial to Evaluate the Safety and Tolerability of CFZ533 (Iscalimab) at Two Dose Levels Administered Subcutaneously in Patients With Sjögren's Syndrome
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Iscalimab (Primary)
- Indications Sjogren's syndrome
- Focus Adverse reactions
- Acronyms A TWINSS Extension Trial; TWINSS Extn
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 04 Sep 2024 Status changed from active, no longer recruiting to completed.
- 30 Jul 2024 Planned End Date changed from 12 Aug 2024 to 22 Aug 2024.
- 30 Jul 2024 Planned primary completion date changed from 12 Aug 2024 to 22 Aug 2024.